Anterior Uveitis - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Anterior Uveitis - Pipeline Review, H2 2015’, provides an overview of the Anterior Uveitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Anterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anterior Uveitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anterior Uveitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anterior Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anterior Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anterior Uveitis Overview 6
Therapeutics Development 7
Pipeline Products for Anterior Uveitis - Overview 7
Pipeline Products for Anterior Uveitis - Comparative Analysis 8
Anterior Uveitis - Therapeutics under Development by Companies 9
Anterior Uveitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Anterior Uveitis - Products under Development by Companies 13
Anterior Uveitis - Companies Involved in Therapeutics Development 14
Aciont Inc. 14
Aldeyra Therapeutics, Inc. 15
EyeGate Pharmaceuticals, Inc. 16
Kineta, Inc. 17
Neuroptis Biotech 18
Virogenomics, Inc. 19
XOMA Corporation 20
Anterior Uveitis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
dalazatide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dexamethasone acetate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
dexamethasone sodium phosphate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
gevokizumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
LME-636 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
NOP-3 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NS-2 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Peptides to Modulate TCR for Uveitis - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Anterior Uveitis - Recent Pipeline Updates 44
Anterior Uveitis - Dormant Projects 55
Anterior Uveitis - Product Development Milestones 56
Featured News & Press Releases 56
May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis 56
Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial 56
Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial 57
Mar 19, 2015: Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases 57
Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program 57
Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences 58
Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis 58
Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis 59
Dec 18, 2012: EyeGate Pharma Enrolls Last Patient In Pivotal Phase III Anterior Uveitis Study Of EGP-437 60
Jan 05, 2012: EyeGate Pharma Initiates Phase III Study Of EGP-437 In Patients With Anterior Uveitis 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63
List Of Tables
Number of Products under Development for Anterior Uveitis, H2 2015 7
Number of Products under Development for Anterior Uveitis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Anterior Uveitis - Pipeline by Aciont Inc., H2 2015 14
Anterior Uveitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2015 15
Anterior Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2015 16
Anterior Uveitis - Pipeline by Kineta, Inc., H2 2015 17
Anterior Uveitis - Pipeline by Neuroptis Biotech, H2 2015 18
Anterior Uveitis - Pipeline by Virogenomics, Inc., H2 2015 19
Anterior Uveitis - Pipeline by XOMA Corporation, H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 29
Anterior Uveitis Therapeutics - Recent Pipeline Updates, H2 2015 44
Anterior Uveitis - Dormant Projects, H2 2015 55
List Of Figures
Number of Products under Development for Anterior Uveitis, H2 2015 7
Number of Products under Development for Anterior Uveitis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Top 10 Targets, H2 2015 22
Number of Products by Stage and Top 10 Targets, H2 2015 22
Number of Products by Top 10 Mechanism of Actions, H2 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 24
Number of Products by Top 10 Routes of Administration, H2 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26
Number of Products by Top 10 Molecule Types, H2 2015 28
Number of Products by Stage and Top 10 Molecule Types, H2 2015 28
